ALN-HBV-02
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Phase 2
Active, not recruiting
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: pegylated interferon-alfa 2a
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04412863
- Locations
- 🇹ðŸ‡
Investigative Site, Khon Kaen, Thailand
ðŸ‡ðŸ‡°Investigative site, Hong Kong, Hong Kong
Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT03672188
- Locations
- 🇹ðŸ‡
Investigative Site, Khon Kaen, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath